An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism

An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism - An observational study for incidence of thromboembolism in lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020194

Enrollment

1000

Registered

2016-01-31

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer, small cell lung cancer

Interventions

edoxaban 60 or 30mg/day for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically or cytologically diagnosed non-small-cell or small cell lung cancer. ECOG PS 0-3 Age over 20 years old. Small cell lung cancer of ED-stage Non-small-cell lung cancer of stage IIIB or IV Reccurence of operation or concurrent chemoradiotherapy Best supportive care patient 2 months or longer expected survival. Written informed consent.

Exclusion criteria

Exclusion criteria: History of allergic reaction for edoxavan Severe renal dysfunction (Ccr under 30 mL/min) Severe liver disease Interstitial pneumonia Plannning for concurrent chemoradiotherapy Started medication or treatment for VTE Active bleeding Severe hypertention A pregnant woman, a woman in breast-feeding Taking aspirin or two kind os antiplatelet drug Acute infectious endocarditis An inappropriate case judged by doctor in charge

Design outcomes

Primary

Measure	Time frame
Frequency of symptomatic and asymptomatic VTE	—

Countries

Japan

Contacts

Public ContactYukari Tsubata

Shimane University Faculty of Medicine Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine

ytsubata@med.shimane-u.ac.jp0853-20-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026